MRK Merck & Co. Inc.

Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care

The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance). With $15 million in funding from the Foundation over five years, the Alliance aims to increase timely access to patient-centered cancer care for vulnerable and underserved populations in the United States.

The following organizations have been selected based on a variety of criteria, including the technical merit of their proposed programs, their organizational capabilities and experience, relationships with community partners, and ability to promote sustainable improvements in the delivery of cancer care.

The University of Michigan School of Nursing, in Ann Arbor, Mich., will serve as the Alliance’s National Program Office.

“With 1.7 million Americans newly diagnosed with cancer each year, there is a great need to improve the quality and delivery of patient-centered care to help address the significant challenges of those facing this diagnosis,” said Julie L. Gerberding, chief patient officer, Merck and chief executive officer, Merck Foundation. “These superb program sites and the National Program Office should accelerate identification and uptake of innovations that benefit patients, improve health communications, and enhance the overall coordination of care.”

Through an independent cross-site evaluation, the Foundation will evaluate the impact of the Alliance and its programs. The evaluation findings and lessons learned will be disseminated to promote best practices in patient-centered cancer care.

About The Merck Foundation

The Merck Foundation is a U.S.-based, private charitable foundation. Established in 1957 by Merck, a global health care leader, the Foundation is funded entirely by the company and is Merck’s chief source of funding support to qualified non-profit charitable organizations. Since its inception, the Merck Foundation has contributed more than $870 million to support important initiatives that address societal needs and are consistent with Merck’s overall mission to help the world be well. For more information, visit www.merckgiving.com.

EN
09/02/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Merck & Co. Inc.

Research Team ACF
  • Research Team ACF

ACF Thematic Oncology Lung Cancer Cough LCC 25042025

Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...

Merck & Co Inc: 3 directors

Three Directors at Merck & Co Inc bought/sold after exercising options 20,194 shares at between 88.250USD and 88.755USD. The significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all...

Research Team ACF
  • Research Team ACF

Regenerative Healthcare - Stem Cells & ALS Thematic 10062024

Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch